Alamar Biosciences, Inc. (NASDAQ:ALMR) Receives $30.00 Average PT from Analysts

Shares of Alamar Biosciences, Inc. (NASDAQ:ALMR) have earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $30.00.

A number of equities analysts have recently issued reports on ALMR shares. Zacks Research raised shares of Alamar Biosciences to a “hold” rating in a research report on Wednesday, May 13th. Bank of America started coverage on shares of Alamar Biosciences in a research report on Tuesday, May 12th. They set a “neutral” rating and a $27.00 price objective on the stock. Wall Street Zen raised shares of Alamar Biosciences to a “hold” rating in a research report on Saturday, April 25th. TD Cowen started coverage on shares of Alamar Biosciences in a research report on Tuesday, May 12th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Stifel Nicolaus started coverage on shares of Alamar Biosciences in a research report on Tuesday, May 12th. They set a “buy” rating and a $28.00 price objective on the stock.

Insider Activity

In other Alamar Biosciences news, major shareholder Innovation Fund Gp Illumina II purchased 235,294 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were acquired at an average price of $17.00 per share, with a total value of $3,999,998.00. Following the transaction, the insider owned 507,076 shares in the company, valued at $8,620,292. The trade was a 86.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nicholas Naclerio purchased 235,294 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $3,999,998.00. Following the transaction, the director owned 507,076 shares in the company, valued at $8,620,292. This represents a 86.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Alamar Biosciences Stock Down 0.9%

ALMR stock opened at $22.00 on Friday. Alamar Biosciences has a 1 year low of $18.84 and a 1 year high of $27.20.

Alamar Biosciences (NASDAQ:ALMR) last released its quarterly earnings data on Friday, May 8th. The company reported ($1.74) earnings per share (EPS) for the quarter. The firm had revenue of $26.04 million for the quarter.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.